Screener
Gyre Therapeutics, Inc. GYRE Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| General and administrative | 7,277 | 15,481 |
| Transaction costs | — | - |
| Total operating expenses | 31,974 | 60,003 |
| (Loss) income from operations | (2,240)) | 302) |
| Other (loss) income, net: | ||
| Interest income | 941 | 1,797 |
| Other expense, net | (488)) | (301)) |
| Change in fair value of warrant liability | 212 | 2,467 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s operating income?
- Gyre Therapeutics, Inc. (GYRE) reported operating income of -$14.36M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s operating income changed year-over-year?
- Gyre Therapeutics, Inc.'s operating income decreased by 541.2% year-over-year, from -$2.24M to -$14.36M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s operating income?
- Over 3 years (2021 to 2025), Gyre Therapeutics, Inc.'s operating income has grown at a -56.8% compound annual growth rate (CAGR), from -$87.89M to $7.08M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Gyre Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude